Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Adaptive Dose, Double-Blind, Placebo-Controlled, SAD and MAD Study to Measure the Safety, Tolerability, Pharmacokinetics and Pharmacological Effects of Orally Administered CORT125134 in Healthy Subjects

NCT03508635 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT03508635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03508635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Adaptive Dose, Double-Blind, Placebo-Controlled, SAD and MAD Study to Measure the Safety, Tolerability, Pharmacokinetics and Pharmacological Effects of Orally Administered CORT125134 in Healthy Subjects
Lead sponsor
Corcept Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2014
Completion date
December 31, 2015
Enrollment
130 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy